18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains

Kenji Matsumura, Masahiro Ono, Hiroyuki Kimura, Masashi Ueda, Yuji Nakamoto, Kaori Togashi, Yoko Okamoto, Masafumi Ihara, Ryosuke Takahashi, Hideo Saji

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We synthesized and evaluated (E)-4-((6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy) benzo[d]thiazol-2-yl)diazenyl)-N,N-dimethylaniline (FPPDB) as a probe for the imaging of neurofibrillary tangles (NFTs) in patients with Alzheimer's disease (AD). In assays using thioflavin S (ThS) as a competitive ligand, FPPDB competed with ThS well and showed high affinity for both tau and Aβ 1-42 aggregates (K i = 13.0 and 20.0 nM, respectively). The results of saturation binding assays also verified that FPPDB bound to both tau and Aβ 1-42 aggregates with high affinity (K d = 44.8 nM and B max = 45.8 pmol/nmol protein for tau aggregates and K d = 45.4 nM and B max = 38.9 pmol/nmol protein for Aβ 1-42 aggregates). Furthermore, [ 18F]FPPDB substantially labeled NFTs and senile plaques in AD brain sections but not control brain sections. In biodistribution experiments using normal mice, [ 18F]FPPDB displayed higher uptake (4.28% ID/g at 2 min postinjection) into and washout (2.53% ID/g at 60 min postinjection) from the brain with time. On the basis of the chemical structure of FPPDB, further increases in selective binding to tau aggregates may lead to the development of more useful probes for the imaging of NFTs in AD brains.

Original languageEnglish
Pages (from-to)58-62
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume3
Issue number1
DOIs
Publication statusPublished - Jan 12 2012
Externally publishedYes

Fingerprint

Neurofibrillary Tangles
Brain
Alzheimer Disease
Imaging techniques
Assays
Amyloid Plaques
Staphylococcal Protein A
tau Proteins
Ligands
benzothiazole
Experiments
thioflavin T
tau-1 monoclonal antibody

Keywords

  • Alzheimer's disease (AD)
  • benzothiazole
  • imaging
  • neurofibrillary tangles (NFTs)
  • PET

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. / Matsumura, Kenji; Ono, Masahiro; Kimura, Hiroyuki; Ueda, Masashi; Nakamoto, Yuji; Togashi, Kaori; Okamoto, Yoko; Ihara, Masafumi; Takahashi, Ryosuke; Saji, Hideo.

In: ACS Medicinal Chemistry Letters, Vol. 3, No. 1, 12.01.2012, p. 58-62.

Research output: Contribution to journalArticle

Matsumura, K, Ono, M, Kimura, H, Ueda, M, Nakamoto, Y, Togashi, K, Okamoto, Y, Ihara, M, Takahashi, R & Saji, H 2012, '18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains', ACS Medicinal Chemistry Letters, vol. 3, no. 1, pp. 58-62. https://doi.org/10.1021/ml200230e
Matsumura, Kenji ; Ono, Masahiro ; Kimura, Hiroyuki ; Ueda, Masashi ; Nakamoto, Yuji ; Togashi, Kaori ; Okamoto, Yoko ; Ihara, Masafumi ; Takahashi, Ryosuke ; Saji, Hideo. / 18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. In: ACS Medicinal Chemistry Letters. 2012 ; Vol. 3, No. 1. pp. 58-62.
@article{b9d7eb94d18048aaae1fa7a9e53467ce,
title = "18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains",
abstract = "We synthesized and evaluated (E)-4-((6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy) benzo[d]thiazol-2-yl)diazenyl)-N,N-dimethylaniline (FPPDB) as a probe for the imaging of neurofibrillary tangles (NFTs) in patients with Alzheimer's disease (AD). In assays using thioflavin S (ThS) as a competitive ligand, FPPDB competed with ThS well and showed high affinity for both tau and Aβ 1-42 aggregates (K i = 13.0 and 20.0 nM, respectively). The results of saturation binding assays also verified that FPPDB bound to both tau and Aβ 1-42 aggregates with high affinity (K d = 44.8 nM and B max = 45.8 pmol/nmol protein for tau aggregates and K d = 45.4 nM and B max = 38.9 pmol/nmol protein for Aβ 1-42 aggregates). Furthermore, [ 18F]FPPDB substantially labeled NFTs and senile plaques in AD brain sections but not control brain sections. In biodistribution experiments using normal mice, [ 18F]FPPDB displayed higher uptake (4.28{\%} ID/g at 2 min postinjection) into and washout (2.53{\%} ID/g at 60 min postinjection) from the brain with time. On the basis of the chemical structure of FPPDB, further increases in selective binding to tau aggregates may lead to the development of more useful probes for the imaging of NFTs in AD brains.",
keywords = "Alzheimer's disease (AD), benzothiazole, imaging, neurofibrillary tangles (NFTs), PET",
author = "Kenji Matsumura and Masahiro Ono and Hiroyuki Kimura and Masashi Ueda and Yuji Nakamoto and Kaori Togashi and Yoko Okamoto and Masafumi Ihara and Ryosuke Takahashi and Hideo Saji",
year = "2012",
month = "1",
day = "12",
doi = "10.1021/ml200230e",
language = "English",
volume = "3",
pages = "58--62",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - 18F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains

AU - Matsumura, Kenji

AU - Ono, Masahiro

AU - Kimura, Hiroyuki

AU - Ueda, Masashi

AU - Nakamoto, Yuji

AU - Togashi, Kaori

AU - Okamoto, Yoko

AU - Ihara, Masafumi

AU - Takahashi, Ryosuke

AU - Saji, Hideo

PY - 2012/1/12

Y1 - 2012/1/12

N2 - We synthesized and evaluated (E)-4-((6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy) benzo[d]thiazol-2-yl)diazenyl)-N,N-dimethylaniline (FPPDB) as a probe for the imaging of neurofibrillary tangles (NFTs) in patients with Alzheimer's disease (AD). In assays using thioflavin S (ThS) as a competitive ligand, FPPDB competed with ThS well and showed high affinity for both tau and Aβ 1-42 aggregates (K i = 13.0 and 20.0 nM, respectively). The results of saturation binding assays also verified that FPPDB bound to both tau and Aβ 1-42 aggregates with high affinity (K d = 44.8 nM and B max = 45.8 pmol/nmol protein for tau aggregates and K d = 45.4 nM and B max = 38.9 pmol/nmol protein for Aβ 1-42 aggregates). Furthermore, [ 18F]FPPDB substantially labeled NFTs and senile plaques in AD brain sections but not control brain sections. In biodistribution experiments using normal mice, [ 18F]FPPDB displayed higher uptake (4.28% ID/g at 2 min postinjection) into and washout (2.53% ID/g at 60 min postinjection) from the brain with time. On the basis of the chemical structure of FPPDB, further increases in selective binding to tau aggregates may lead to the development of more useful probes for the imaging of NFTs in AD brains.

AB - We synthesized and evaluated (E)-4-((6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy) benzo[d]thiazol-2-yl)diazenyl)-N,N-dimethylaniline (FPPDB) as a probe for the imaging of neurofibrillary tangles (NFTs) in patients with Alzheimer's disease (AD). In assays using thioflavin S (ThS) as a competitive ligand, FPPDB competed with ThS well and showed high affinity for both tau and Aβ 1-42 aggregates (K i = 13.0 and 20.0 nM, respectively). The results of saturation binding assays also verified that FPPDB bound to both tau and Aβ 1-42 aggregates with high affinity (K d = 44.8 nM and B max = 45.8 pmol/nmol protein for tau aggregates and K d = 45.4 nM and B max = 38.9 pmol/nmol protein for Aβ 1-42 aggregates). Furthermore, [ 18F]FPPDB substantially labeled NFTs and senile plaques in AD brain sections but not control brain sections. In biodistribution experiments using normal mice, [ 18F]FPPDB displayed higher uptake (4.28% ID/g at 2 min postinjection) into and washout (2.53% ID/g at 60 min postinjection) from the brain with time. On the basis of the chemical structure of FPPDB, further increases in selective binding to tau aggregates may lead to the development of more useful probes for the imaging of NFTs in AD brains.

KW - Alzheimer's disease (AD)

KW - benzothiazole

KW - imaging

KW - neurofibrillary tangles (NFTs)

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84855879380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855879380&partnerID=8YFLogxK

U2 - 10.1021/ml200230e

DO - 10.1021/ml200230e

M3 - Article

VL - 3

SP - 58

EP - 62

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 1

ER -